1

- 1 An expanded population of CD8^{dim} T cells with features of mitochondrial
- 2 dysfunction and senescence is associated with persistent HIV-associated

3 Kaposi's sarcoma under ART

- 4 Genevieve T CLUTTON*¶, Ann Marie K WEIDEMAN†, Nilu P GOONETILLEKE*‡,
- 5 Toby MAURER§
- 6 *Department of Microbiology & Immunology, UNC Chapel Hill School of Medicine,
- 7 Chapel Hill, North Carolina 27599, USA
- 8 †Department of Biostatistics and Center for AIDS Research, UNC Chapel Hill, Chapel
- 9 Hill, North Carolina 27599, USA
- 10 ‡UNC HIV Cure Center, UNC Institute of Global Health and Infectious Diseases, Chapel
- 11 Hill, North Carolina 27599, USA
- 12 §Department of Dermatology, Indiana University, Indiana, USA
- 13 ¶Corresponding author. Email: <u>gen_clutton@med.unc.edu</u>

14 Abstract

HIV-associated Kaposi's sarcoma (KS), which is caused by Kaposi's sarcoma-associated 15 herpesvirus, usually arises in the context of uncontrolled HIV replication and 16 17 immunosuppression. However, disease occasionally persists in individuals with durable HIV viral suppression and CD4 T cell recovery under anti-retroviral therapy (ART). The 18 underlying mechanisms associated with this persistence are unclear. Suppression of viral 19 infections can be mediated by CD8 T cells that detect infected cells via their T cell receptor 20 21 and the CD8 co-receptor. However, CD8 T cells exhibit signs of functional exhaustion in untreated HIV infection that may not be fully reversed under ART. To investigate whether 22 persistent KS under ART was associated with phenotypic and functional perturbations of 23 CD8 T cells, we performed a cross-sectional study comparing HIV-infected individuals with 24 persistent KS under effective ART (HIV+ KS+) to HIV-infected individuals receiving 25 effective ART with no documented history of KS (HIV+ KS^{neg}). A subset of T cells with 26 low cell surface expression of CD8 ("CD8^{dim} T cells") was expanded in HIV+ KS+ 27 compared with HIV+ KS^{neg} participants. Relative to CD8^{bright} T cells, CD8^{dim} T cells 28 29 exhibited signs of senescence (CD57) and mitochondrial perturbations (PGC-1a, 30 MitoTracker) ex vivo. Mitochondrial activity (MitoTracker) was also reduced in proliferating CD8^{dim} T cells. These findings indicate that an expanded CD8^{dim} T cell 31 population displaying features of senescence and mitochondrial dysfunction is associated 32 with KS persistence under ART. CD8 co-receptor down-modulation may be symptomatic 33 34 of ongoing disease.

35 Running title: CD8^{dim} T cells expanded in HIV-associated KS

- 36 Keywords: T cells; CD8 co-receptor; KSHV; Kaposi's sarcoma; Tumor immunity; HIV;
- 37 Metabolism; Senescence; Mitochondria; MitoTracker; PGC-1α; Proliferation.

38

Funding: This study was supported by a Young Investigator Pilot Award awarded to G.T.C. 39 by the AIDS and Cancer Specimen Resource, funded by the National Cancer Institute (UM1 40 41 CA181255). Initial sample collection was supported by NIH grants U01 AI117844, U01 AI095052, and R01 HL132791. The UNC Flow Cytometry Core Facility is supported in part 42 by P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger 43 Comprehensive Cancer Center and by the Center for AIDS Research award number 44 5P30AI050410. Statistical expertise was provided by the University of North Carolina at 45 Chapel Hill Center for AIDS Research, an NIH funded program P30 AI050410. The content 46 47 is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. 48

49

- 50 Abbreviations used in this article
- 51 ART (HIV) Anti-retroviral therapy
- 52 CFSE carboxyfluorescein succinimidyl ester
- 53 KS Kaposi's sarcoma
- 54 KSHV Kaposi's sarcoma-associated herpesvirus, also known as HHV-8
- 55 MTDR MitoTracker® Deep Red
- 56 PBMC Peripheral blood mononuclear cells
- 57 PHA Phytohaemagglutinin
- 58 TCR T cell receptor

59

61 Introduction

Kaposi's sarcoma (KS), a cancer of epithelial and endothelial cells characterized by dark 62 63 plaques and nodules, is a common AIDS-related morbidity in individuals with untreated HIV infection^[1]. However, while the etiologic agent of KS, Kaposi's sarcoma-associated 64 herpesvirus (KSHV), generates a lifelong infection, it rarely causes disease in 65 66 immunocompetent individuals. The introduction of HIV antiretroviral therapy (ART), and resulting immune recovery in treated individuals, has been accompanied by a steep decline 67 in HIV-associated KS cases ^[2, 3]. However, a minority of HIV-infected KSHV-seropositive 68 individuals experience persistent KS despite durable HIV suppression and CD4 T cell 69 recovery under ART^[4-6]. The underlying causes of this failure to achieve KS remission are 70 not currently understood. The recent discovery that latent KSHV can be reactivated by 71 72 proteins from SARS-CoV-2 and some anti-COVID-19 drugs further underscores the need to better understand the control and pathogenesis of KS^[7]. 73

74 CD8 T cells are major mediators of anti-viral immunity, detecting virus-infected cells via 75 the T cell receptor (TCR) and CD8-co-receptor. KSHV-infected individuals harbor CD8 T 76 cells capable of secreting antiviral cytokines and killing cells expressing KSHV antigens in vitro [8-14]. These KSHV-specific CD8 T cells are detected at higher frequencies in KSHV-77 78 seropositive individuals who do not have KS compared with individuals with active disease 79 ^[14]. Collectively, these observations suggest that in immunocompetent individuals, CD8 T 80 cells may play a lifelong role in preventing KSHV from causing disease. However, during untreated progressive HIV infection, T cells exhibit signs of functional exhaustion that may 81 not be fully reversed by ART^[15-19]. Notably, these defects include metabolic perturbations 82

4

such as impaired mitochondrial oxidative phosphorylation and increased reliance on 83 84 glycolysis ^[20, 21]. Mitochondrial metabolism is crucial for lasting CD8 T cell control of viral infections: while effector T cells upregulate glycolysis to rapidly generate ATP, memory T 85 cells use mitochondrial oxidative phosphorylation to support their long-term persistence ^{[22-} 86 ^{26]}. Indeed, loss of mitochondrial mass is associated with senescence, a state where T cells 87 lose proliferative capacity ^[27]. Defects in CD8 T cell metabolic fitness in HIV-infected 88 89 individuals on ART could be particularly detrimental in the tumor microenvironment, where rapidly proliferating malignant cells create an environment of hypoxia and mitochondrial 90 stress [28-30]. 91

We investigated the possibility that altered CD8 T cell phenotype and metabolism could be associated with persistent KS in HIV-infected individuals on ART by comparing HIVinfected individuals with and without KS. We observed an elevated frequency of CD8^{dim} T cells in individuals with HIV-associated KS. These cells expressed elevated levels of the senescence marker CD57, lower levels of the mitochondrial master-regulator PGC-1 α , and exhibited reduced mitochondrial activity. Persistent KS is therefore associated with the expansion of a subset of CD8 T cells with metabolic hallmarks of senescence.

5

100 Materials and Methods

101 *Study participants:*

HIV-1-infected participants with biopsy-confirmed KS ("HIV+ KS+") were recruited from 102 103 primary care practices in San Francisco and the adjacent counties, UCLA-related primary 104 care clinics, and the Study of the Consequences of the Protease Inhibitor Era (SCOPE). 105 Participants had received ART (including protease inhibitors, NNRTIs, and early integrase 106 inhibitors) and maintained plasma viral loads <75 copies/ml for ≥ 2 years. CD4 T cell counts 107 were $\geq 340/\mu$ l. All participants had stage 1 tumors according to ACTG criteria (tumor confined to skin and/or lymph nodes and/or minimal oral disease) ^[31]. The study was 108 109 approved by the Institutional Review Board of the University of California, San Francisco 110 (approval no. 10-02850). HIV-1-infected participants with no documented history of KS 111 ("HIV+ KS^{neg}") were recruited from the UNC HIV Clinical Trials Unit. Participants had received ART for ≥ 2 years and maintained plasma viral loads <50 copies/ml and CD4 T cell 112 113 counts $>300/\mu$ l for ≥ 6 months. Participant characteristics are detailed in Table 1. Initial 114 collection of UNC samples was approved by the UNC Institutional Review Board (ethics 115 numbers 11-0228; 14-0741; and 15-1626). Retrospective use of all samples was approved 116 by the UNC Institutional Review Board (ethics number 17-2415).

117 *CD8 T cell phenotyping:*

Cryopreserved peripheral blood mononuclear cells (PBMC) were rested in R10 medium
(RPMI 1640 supplemented with 10% fetal bovine serum; penicillin/streptomycin; 2 mM L-

120 glutamine; 10 mM sodium pyruvate; and 10 mM HEPES) at 37°C overnight. PBMC were

121	stained with Zombie NIR viability dye, then cell surface antibodies CD3-PerCP-Cy5.5
122	(clone UCHT1); CD4-PE-Cy5 (OKT4); CD8-Brilliant Violet 510 (SK1); CD14 (M5E2),
123	CD16 (3G8), CD19 (HIB19), and CD56 (HCD56)-Brilliant Violet 650; CD45RO-PE
124	(UCHL1); and CD57-PE-Dazzle 594 (HNK-1) (all Biolegend). Cells were stained
125	intracellularly with T-bet-Brilliant Violet 421 (4B10; Biolegend); Eomes-eFluor 660
126	(WD1928; eBioscience); polyclonal anti-PGC-1a antibody (Santa Cruz Biotechnology); and
127	PE-Cy7 secondary antibody. Samples were acquired on an LSRII flow cytometer and
128	analyzed using FlowJo 10 (BD Biosciences). Live lymphocytes were defined by dim
129	staining with Zombie viability dye, forward scatter height vs area (to identify single events),
130	and forward scatter versus side scatter. CD8 T lymphocytes were defined as CD3+ CD4-
131	CD14/16/19/56- and CD8 bright or dim. For phenotypic markers, positive events were gated
132	using fluorescence minus one controls (Supplementary Figure 1).

133 Table 1: Participant Characteristics

	HIV+KS+(n=8)	$HIV+KS^{neg} (n = 12)$
Age in years; median (range)	57 (35 - 65)	48 (33 - 66)
Male sex	8/8	9/12
Viral load (copies/ml)	<70 (<70 - 97)	<50
CD4 count (cells/µl)	677 (340 - 1331)	769 (491 – 1289)
KS stage	ACTG stage 1	N/A

134

135 *CD8 T cell proliferation:*

136 Cryopreserved PBMC were rested overnight, then pulsed under rotation with 5 μ M 137 carboxyfluorescein succinimidyl ester (CFSE, Biolegend). Staining was quenched with ice-

7

cold R10. Cells were stimulated with vehicle (0.5% DMSO) or 3 µg/ml phytohaemagglutinin 138 (PHA, Sigma) for 5 days at 37°C. PBMC were stained with Zombie NIR; CD3-PE-Cy7; 139 140 CD4-BV421; CD8-BV510; CD14, CD16, CD19, and CD56-BV650 (clones as previously; Biolegend). To assess mitochondrial polarization, cells were stained with 25 nM 141 142 MitoTracker® Deep Red (MTDR, Molecular Probes) at 37°C. Cells were acquired on an LSR Fortessa and analyzed using FlowJo 10 and Modfit LT 4 (Verity Software House). 143 144 Proliferation was assessed using proliferation index, defined as the mean number of proliferative cycles undergone by each proliferating cell ^[32]. MTDR^{high} cells were gated 145 using a previously described method ^[33]. Briefly, after excluding outliers (the brightest and 146 147 dimmest 0.1% of events), the fluorescence intensities of the brightest and dimmest cells were used to calculate the fluorescence range (brightest – dimmest). Cells that fell within the top 148 90% of this range were considered MTDR^{high} (Supplementary Figure 2). 149

150 *Statistical analysis:*

Data were analyzed using GraphPad Prism version 8. Between-group differences were analyzed using an exact, two-sided Mann-Whitney U test. Within-individual differences between CD8^{bright} and CD8^{dim} T cells were analyzed using an exact, two-sided Wilcoxon signed-rank test. The monotonic (strictly increasing or decreasing) relationship between variables such as CD8^{dim} percentage and proliferation index was assessed using Spearman's rank correlation coefficient.

8

158 **Results**

159 *CD8^{dim} T cells are expanded in HIV+ individuals with persistent KS, and exhibit features of*

160 *senescence*

We compared the phenotype of CD8 T cells between HIV-infected individuals with 161 162 persistent KS under ART (HIV+ KS+) and HIV-infected individuals receiving ART with no documented history of KS (HIV+ KSneg). CD8 T cells were defined as CD3+ CD8+ CD4-163 164 CD14/CD16/CD56- to exclude NKT cells (Supplementary Figure 1). We observed two populations of CD8 T cells: a CD8^{bright} subset with high cell surface expression of CD8 and 165 a CD8^{dim} subset with lower surface expression (Fig. 1A). CD3*ɛ*, which forms part of the 166 167 TCR complex, was also expressed at a lower level on the surface of CD8^{dim} cells compared with $CD8^{bright}$ cells (median of differences = -4358 MFI; Wilcoxon signed-rank test p = 168 169 0.007; Supplementary Figure 3). The CD8^{dim} subset was significantly expanded, as a percentage of total CD8 T cells, in HIV+ KS+ compared with HIV+ KS^{neg} participants 170 171 (difference of medians = 12.28%; Mann-Whitney test p = 0.0006; Fig. 1B). Since highly 172 differentiated T cells accumulate during chronic untreated infections ^[34, 35], we next compared the differentiation state of CD8^{bright} and CD8^{dim} cells within participants. CD57 173 174 expression was higher on $CD8^{dim}$ than $CD8^{bright}$ T cells (median of differences = 8%; Wilcoxon signed-rank test p = 0.008), indicating that late-differentiated or senescent cells 175 were overrepresented in the CD8^{dim} population (Fig. 1C and Supplementary Figure 3). 176 177 Supporting this observation, Eomesodermin (Eomes), a transcription factor expressed in terminal memory cells, was expressed in a higher percentage of CD8^{dim} than CD8^{bright} cells 178 (median of differences = 13.5%; Wilcoxon signed-rank test p = 0.008, Fig. 1D and 179

180 Supplementary Figure 3)^[36, 37]. T-bet, a transcription factor expressed by effector cells, was





183 Figure 1. CD8^{dim} cells with low mitochondrial activity are expanded in individuals

184 with persistent KS. A) Representative plots showing CD8^{bright} and CD8^{dim} T cells in a

10

185	HIV+ KS ^{neg} and a HIV+ KS+ participant. B) The frequency of CD8 ^{dim} T cells (as a
186	percentage of total CD8 T cells) is significantly elevated in HIV+ individuals with
187	persistent KS under ART (KS+; $n = 7$) compared with the KS ^{neg} group ($n = 8$) (difference
188	of medians= 12.28%; Mann-Whitney test). C) A significantly higher percentage of CD8 ^{dim}
189	T cells express CD57 compared with $CD8^{bright}$ T cells (median of differences = 8%;
190	Wilcoxon signed-rank test). D) A significantly higher percentage of CD8 ^{dim} T cells
191	express Eomes compared with $CD8^{bright}$ T cells (median of differences = 13.5%; Wilcoxon
192	signed-rank test). E) Expression of the mitochondrial master regulator PGC-1 α is
193	significantly reduced in $CD8^{dim}$ T cells (median of differences = -789 MFI; Wilcoxon
194	signed-rank test). F) The frequency of MitoTracker Deep Red high cells is significantly
195	lower for CD8 ^{dim} T cells compared with CD8 ^{bright} T cells (median of differences = -8.99% ;
196	Wilcoxon signed-rank test). Gray open squares, HIV+ KS+ participants; black circles,
197	HIV+ KS ^{neg} participants.

198

199 *CD8^{dim} T cells have an altered mitochondrial phenotype*

The development, persistence, and recall function of memory CD8 T cells is highly dependent on mitochondrial metabolism ^[24, 38]. Compared with CD8^{bright} T cells, expression of the mitochondrial master regulator PGC-1 α was significantly reduced in CD8^{dim} T cells (median of differences = -789 MFI; Wilcoxon signed-rank test p = 0.001; Fig. 1E). To further investigate mitochondrial phenotype in CD8^{bright} vs CD8^{dim} T cells, we used MitoTracker® Deep Red (MTDR), which selectively binds actively respiring mitochondria [^{39]}. MTDR^{high} cells were defined using a previously described objective gating strategy (^[33];

Supplementary Figure 2). The frequency of MTDR^{high} cells was lower in the CD8^{dim} T cell population than CD8^{bright} T cells (median of differences = -8.99%; Wilcoxon signed-rank test p = 0.002; Fig. 1F). These observations indicate that individuals with HIV-associated KS have an expanded population of CD8^{dim} T cells with a highly differentiated/senescent phenotype and reduced mitochondrial activity.

212

213 *Mitochondrial activity is reduced in CD8^{dim} proliferating cells*

We next examined whether cell surface expression of the CD8 co-receptor was related to replicative capacity and mitochondrial activity in proliferating cells. PBMC were stimulated with the polyclonal stimulus PHA for five days and proliferation was measured by CFSE dilution (Fig. 2A). Proliferative capacity was reported as proliferation index (the mean number of proliferative cycles undergone by each responding cell).

CD8 T cells that had proliferated (CFSE^{low}) exhibited greater mitochondrial activity (% of 219 cells MTDR^{high}) than non-proliferating (CFSE^{high}) cells (median of differences = 23.25%; 220 221 Wilcoxon signed-rank test p = 0.002; Fig. 2B). There was a strong positive correlation 222 between mitochondrial activity of all CD8 T cells and proliferation index at day five, 223 demonstrating the importance of mitochondrial respiration to CD8 T cell proliferation ($r_s =$ 0.75, p = 0.017; Fig. 2C) ^[26]. Conversely, there was a strong negative correlation between 224 mitochondrial activity of all CD8 T cells and the percentage of CD8^{dim} T cells in the culture 225 at five days ($r_s = -0.75$, p = 0.017; Fig. 2D), suggesting that low CD8 expression is associated 226 with reduced mitochondrial activity. Further supporting this hypothesis, CD8^{dim} cells that 227

12

had proliferated exhibited lower mitochondrial activity (% MTDR^{high}) than CD8^{bright} cells that had proliferated (median of differences = -23.35%; Wilcoxon signed-rank test p = 0.002; Fig. 2E). There was also evidence of a moderate negative correlation between the percentage of CD8^{dim} T cells in the culture and proliferation index (r_s = -0.61, p = 0.067; Fig. 2F). Collectively these results indicate that low surface expression of CD8 is associated with reduced mitochondrial respiration and replicative capacity of proliferating CD8 T cells.





A) Histograms showing CFSE dilution in unstimulated and PHA-stimulated CD8 T cells.

- B) MitoTracker Deep Red (MTDR) fluorescence in PHA-stimulated proliferating
- 238 (CFSE^{low}) cells. A significantly higher percentage of proliferating (CFSE^{low}) CD8 T cells
- are $MTDR^{high}$ compared with non-proliferating (CFSE^{high}) CD8 T cells, indicating that
- 240 proliferating cells have higher mitochondrial activity (n = 10; median of differences =

13

241	23.25%; Wilcoxon signed-rank test). C) Positive association between mitochondrial					
242	activity (% MTDR ^{high}) of all CD8 T cells in the culture and the proliferation index of					
243	proliferating cells in response to PHA stimulation (Spearman correlation). D) Negative					
244	association between mitochondrial activity and the frequency of CD8 ^{dim} T cells following					
245	stimulation with PHA (Spearman correlation). E) The frequency of MTDR ^{high} cells,					
246	comparing CD8 ^{bright} and CD8 ^{dim} proliferating (CFSE ^{low}) cells. CD8 ^{dim} proliferating cells					
247	are significantly less likely to be MTDR ^{high} , indicating lower mitochondrial activity					
248	(median of differences = -23.35%; Wilcoxon signed-rank test). F) Proliferation index of					
249	PHA-stimulated CD8 T cells versus the frequency of CD8 ^{dim} T cells in the culture					
250	(Spearman correlation). Gray open squares, HIV+ KS+ participants; black circles, HIV+					
251	KS ^{neg} participants.					

253 **Discussion**

The underlying causes of persistent KS in a minority of HIV-infected individuals with durable viral suppression and CD4 T cell recovery under ART are unknown. Here, we have identified an expanded population of CD8^{dim} T cells with phenotypic characteristics of senescence and mitochondrial dysfunction in these individuals.

The CD8 co-receptor amplifies signals through the TCR ^[40, 41]. Following antigenic 258 259 stimulation (e.g. by a virus-infected cell), CD8, along with the TCR, is downregulated from the cell surface, possibly to limit the strength or duration of signaling ^[42-44]. This suggests 260 that the expansion of CD8^{dim} T cells may be a response to high and/or persistent antigen 261 stimulation. Supporting this hypothesis, elevated frequencies of CD8^{dim} T cells have been 262 263 reported during acute HIV infection, and in children exposed to a high cumulative pathogen burden during the first years of life ^[45, 46]. Our observation that CD8^{dim} T cells are also 264 expanded in individuals with persistent KS under ART supports the notion that CD8 265 266 downregulation is a general phenomenon in settings of unresolved infection.

267 Chronic viral infections are also associated with CD8 T cell terminal differentiation and/or 268 senescence^[47]. Senescent CD8 T cells exhibit reduced expression of PGC-1 α , the master-269 regulator of mitochondrial biogenesis, and lower mitochondrial activity ^[27, 48]. Conversely, 270 forced expression of PGC-1 α promotes robust CD8 T cell memory responses ^[49]. These 271 observations underscore the importance of mitochondrial respiration for long-term CD8 T 272 cell anti-viral function. In the setting of persistent KS, we observed that the expanded CD8^{dim} 273 T cell population expressed high levels of Eomesodermin and CD57, proteins respectively

15

associated with terminal differentiation and senescence, and had reduced expression of PGC-1 α . CD8^{dim} cells also contained fewer respiring mitochondria both *ex vivo* and when proliferating. Our data suggest that mitochondrial dysfunction may underlie the accumulation of senescent CD8 T cells that has previously been reported in KS ^[34]; however, this hypothesis must be tested in future studies. It is unclear from our current data whether CD8 expression directly regulates mitochondrial activity in CD8 T cells.

A key question is whether the CD8^{dim} T cells we observed are specific for KSHV, for HIV, 280 281 or for other persistent viral infections such as CMV, which is highly seroprevalent in HIVinfected individuals ^[50]. It is possible that CD8 down-modulation could be driven by multiple 282 concurrent infections, by ongoing immune activation, or by a combination of factors. In this 283 initial study, we were unable to determine whether the CD8^{dim} T cells we observed were 284 285 KSHV-specific, as KSHV is a large virus, and immunoprevalent epitopes eliciting responses in a high percentage of seropositive individuals have not yet been identified. The question 286 of the antigen specificity of CD8^{dim} T cells will be the subject of subsequent investigations. 287

Our work has some limitations. As this was an observational study, we were unable to determine whether the expansion of CD8^{dim} T cells plays a causative role in the failure to control KSHV under ART or is a consequence of this lack of suppression. Due to lack of available tissue, we were unable to assess whether CD8 T cells infiltrating the tumor microenvironment also exhibit a CD8^{dim} phenotype. This question, together with the antigen specificity of CD8^{dim} T cells and a direct examination of their functional profile, is the subject of ongoing investigations. If KSHV-specific CD8 T cells infiltrating the tumor

16

295	microenvironment express low levels of CD8 and exhibit reduced mitochondrial activity,
296	this will have important implications for immunotherapeutic approaches to KS treatment.

297

298

299 Acknowledgements

Author contributions: The manuscript was written by G.T.C., A.M.W., N.P.G., and T.M.

301 G.T.C. and N.P.G. contributed to study design. G.T.C. performed experimentation and

- 302 collection of data. G.T.C. and A.M.W. performed the statistical analyses. G.T.C. acquired
- 303 funding for the study. T.M. facilitated participant recruitment and sample collection. All
- authors provided review of the final manuscript. We thank Joann Kuruc and Cynthia Gay
- 305 for their work recruiting participants to UNC cohorts that were retrospectively utilized for
- this study.
- 307 Conflicts of interest: There are no conflicts of interest.

309 **References**

- 1. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R,
- 311 Goedert JJ, Engels EA. Cancer burden in the HIV-infected population in the United States. J Natl
- 312 *Cancer Inst* 2011; 103(9):753-762.
- 2. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-
- Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst
- 315 2002; 94(16):1204-1210.
- 316 3. Franceschi S, Maso LD, Rickenbach M, Polesel J, Hirschel B, Cavassini M, Bordoni A, Elzi L, Ess S,
- 317 Jundt G, Mueller N, Clifford GM. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before
- and after highly active antiretroviral therapy. *Br J Cancer* 2008; 99(5):800-804.
- 4. Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low
- 320 viral load. N Engl J Med 2007; 357(13):1352-1353.
- 321 5. Mani D, Neil N, Israel R, Aboulafia DM. A retrospective analysis of AIDS-associated Kaposi's
- 322 sarcoma in patients with undetectable HIV viral loads and CD4 counts greater than 300
- 323 cells/mm(3). Journal of the International Association of Physicians in AIDS Care (Chicago, Ill :
- 324 *2002)* 2009; 8(5):279-285.
- 325 6. von Braun A, Braun DL, Kamarachev J, Gunthard HF. **New onset of kaposi sarcoma in a human**
- 326 immunodeficiency virus-1-infected homosexual man, despite early antiretroviral treatment,
- 327 sustained viral suppression, and immune restoration. Open forum infectious diseases 2014;
- 328 1(1):ofu005.
- 329 7. Chen J, Dai L, Barrett L, James J, Plaisance-Bonstaff K, Post SR, Qin Z. SARS-CoV-2 proteins and
- 330 anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus. *Communications biology*
- 331 2021; 4(1):682.

- 8. Osman M, Kubo T, Gill J, Neipel F, Becker M, Smith G, Weiss R, Gazzard B, Boshoff C, Gotch F.
- 333 Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol 1999;
- 334 73(7):6136-6140.
- 335 9. Bihl F, Narayan M, Chisholm JV, 3rd, Henry LM, Suscovich TJ, Brown EE, Welzel TM, Kaufmann
- 336 DE, Zaman TM, Dollard S, Martin JN, Wang F, Scadden DT, Kaye KM, Brander C. Lytic and latent
- 337 antigens of the human gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and
- 338 Epstein-Barr virus induce T-cell responses with similar functional properties and memory
- 339 **phenotypes**. *J Virol* 2007; 81(9):4904-4908.
- 10. Bihl F, Berger C, Chisholm JV, 3rd, Henry LM, Bertisch B, Trojan A, Nadal D, Speck RF, Flepp M,
- 341 Brander C, Mueller NJ, Swiss HIVCS. Cellular immune responses and disease control in acute
- 342 **AIDS-associated Kaposi's sarcoma**. *AIDS* 2009; 23(14):1918-1922.
- 11. Robey RC, Lagos D, Gratrix F, Henderson S, Matthews NC, Vart RJ, Bower M, Boshoff C, Gotch
- 344 FM. The CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is
- skewed towards early and late lytic antigens. *PLoS One* 2009; 4(6):e5890.
- 12. Lepone L, Rappocciolo G, Knowlton E, Jais M, Piazza P, Jenkins FJ, Rinaldo CR. Monofunctional
- 347 and polyfunctional CD8+ T cell responses to human herpesvirus 8 lytic and latency proteins.
- 348 *Clinical and vaccine immunology : CVI* 2010; 17(10):1507-1516.
- 13. Lepone LM, Rappocciolo G, Piazza PA, Campbell DM, Jenkins FJ, Rinaldo CR. Regulatory T Cell
- 350 Effect on CD8(+) T Cell Responses to Human Herpesvirus 8 Infection and Development of
- 351 **Kaposi's Sarcoma**. *AIDS Res Hum Retroviruses* 2017; 33(7):668-674.
- 14. Lambert M, Gannage M, Karras A, Abel M, Legendre C, Kerob D, Agbalika F, Girard PM, Lebbe
- 353 C, Caillat-Zucman S. Differences in the frequency and function of HHV8-specific CD8 T cells
- between asymptomatic HHV8 infection and Kaposi sarcoma. *Blood* 2006; 108(12):3871-3880.

355	15. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie
356	AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM,
357	Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD. PD-1 expression on HIV-specific T
358	cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443(7109):350-
359	354.
360	16. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart
361	E, Sepulveda H, Balderas RS, Routy JP, Haddad EK, Sekaly RP. Upregulation of PD-1 expression on
362	HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nature medicine 2006;
363	12(10):1198-1202.
364	17. Day CL, Kiepiela P, Leslie AJ, van der Stok M, Nair K, Ismail N, Honeyborne I, Crawford H,
365	Coovadia HM, Goulder PJ, Walker BD, Klenerman P. Proliferative capacity of epitope-specific CD8
366	T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type
367	1 infection. J Virol 2007; 81(1):434-438.
368	18. Migueles SA, Weeks KA, Nou E, Berkley AM, Rood JE, Osborne CM, Hallahan CW, Cogliano-
369	Shutta NA, Metcalf JA, McLaughlin M, Kwan R, Mican JM, Davey RT, Jr., Connors M. Defective
370	human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and
371	cytotoxicity are not restored by antiretroviral therapy. J Virol 2009; 83(22):11876-11889.
372	19. Gaiha GD, McKim KJ, Woods M, Pertel T, Rohrbach J, Barteneva N, Chin CR, Liu D, Soghoian
373	DZ, Cesa K, Wilton S, Waring MT, Chicoine A, Doering T, Wherry EJ, Kaufmann DE, Lichterfeld M,
374	Brass AL, Walker BD. Dysfunctional HIV-Specific CD8(+) T Cell Proliferation Is Associated with
375	Increased Caspase-8 Activity and Mediated by Necroptosis. Immunity 2014; 41(6):1001-1012.
376	20. Korencak M, Byrne M, Richter E, Schultz BT, Juszczak P, Ake JA, Ganesan A, Okulicz JF, Robb
377	ML, de Los Reyes B, Winning S, Fandrey J, Burgess TH, Esser S, Michael NL, Agan BK, Streeck H.

- 378 Effect of HIV infection and antiretroviral therapy on immune cellular functions. JCI Insight 2019;
- 379 4(12).
- 380 21. Angin M, Volant S, Passaes C, Lecuroux C, Monceaux V, Dillies M-A, Valle-Casuso JC, Pancino
- 381 G, Vaslin B, Le Grand R, Weiss L, Goujard C, Meyer L, Boufassa F, Müller-Trutwin M, Lambotte O,
- 382 Sáez-Cirión A. Metabolic plasticity of HIV-specific CD8+ T cells is associated with enhanced
- **antiviral potential and natural control of HIV-1 infection**. *Nature Metabolism* 2019; 1(7):704-716.
- 384 22. Cham CM, Gajewski TF. Glucose availability regulates IFN-gamma production and p70S6
- kinase activation in CD8+ effector T cells. *J Immunol* 2005; 174(8):4670-4677.
- 23. Jacobs SR, Herman CE, Maciver NJ, Wofford JA, Wieman HL, Hammen JJ, Rathmell JC. Glucose
- 387 uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and
- 388 independent pathways. J Immunol 2008; 180(7):4476-4486.
- 389 24. van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E, Pearce EJ, Pearce EL.
- 390 Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development.
- 391 *Immunity* 2012; 36(1):68-78.
- 392 25. van der Windt GJ, O'Sullivan D, Everts B, Huang SC, Buck MD, Curtis JD, Chang CH, Smith AM,
- Ai T, Faubert B, Jones RG, Pearce EJ, Pearce EL. CD8 memory T cells have a bioenergetic
- 394 advantage that underlies their rapid recall ability. *Proc Natl Acad Sci U S A* 2013.
- 26. Chang CH, Curtis JD, Maggi LB, Jr., Faubert B, Villarino AV, O'Sullivan D, Huang SC, van der
- Windt GJ, Blagih J, Qiu J, Weber JD, Pearce EJ, Jones RG, Pearce EL. **Posttranscriptional control of**
- **T cell effector function by aerobic glycolysis**. *Cell* 2013; 153(6):1239-1251.
- 398 27. Callender LA, Carroll EC, Bober EA, Akbar AN, Solito E, Henson SM. Mitochondrial mass
- **governs the extent of human T cell senescence**. *Aging cell* 2020; 19(2):e13067.

- 400 28. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-
- 401 Myc cooperatively induce vascular endothelial growth factor and metabolic switches
- 402 hexokinase 2 and pyruvate dehydrogenase kinase 1. *Mol Cell Biol* 2007; 27(21):7381-7393.
- 403 29. Delgado T, Carroll PA, Punjabi AS, Margineantu D, Hockenbery DM, Lagunoff M. Induction of
- 404 the Warburg effect by Kaposi's sarcoma herpesvirus is required for the maintenance of latently
- 405 infected endothelial cells. *Proc Natl Acad Sci U S A* 2010; 107(23):10696-10701.
- 406 30. Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, Chiang YJ,
- 407 Corona AL, Gemta LF, Vincent BG, Wang RC, Kim B, Hong J, Chen CL, Bullock TN, Irish JM, Rathmell
- 408 WK, Rathmell JC. Mitochondrial dysregulation and glycolytic insufficiency functionally impair
- 409 **CD8 T cells infiltrating human renal cell carcinoma**. *JCI Insight* 2017; 2(12).
- 410 31. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency
- 411 syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials
- 412 **Group Oncology Committee**. *Journal of clinical oncology : official journal of the American Society*
- 413 *of Clinical Oncology* 1989; 7(9):1201-1207.
- 414 32. Roederer M. Interpretation of cellular proliferation data: avoid the panglossian. *Cytometry*
- 415 Part A : the journal of the International Society for Analytical Cytology 2011; 79(2):95-101.
- 416 33. Clutton G, Mollan K, Hudgens M, Goonetilleke N. A Reproducible, Objective Method Using
- 417 MitoTracker(R) Fluorescent Dyes to Assess Mitochondrial Mass in T Cells by Flow Cytometry.
- 418 Cytometry Part A : the journal of the International Society for Analytical Cytology 2019; 95(4):450-
- 419 456.
- 420 34. Unemori P, Leslie KS, Hunt PW, Sinclair E, Epling L, Mitsuyasu R, Effros RB, Dock J, Dollard SG,
- 421 Deeks SG, Martin JN, Maurer TA. Immunosenescence is associated with presence of Kaposi's
- sarcoma in antiretroviral treated HIV infection. *AIDS* 2013; 27(11):1735-1742.

- 423 35. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, Dong T, Chesney G, Waters A,
- 424 Easterbrook P, Dunbar PR, Shepherd D, Cerundolo V, Emery V, Griffiths P, Conlon C, McMichael
- 425 AJ, Richman DD, Rowland-Jones SL, Appay V. Immune activation and CD8+ T-cell differentiation
- 426 towards senescence in HIV-1 infection. *PLoS Biol* 2004; 2(2):E20.
- 427 36. Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE, Bikoff EK, Robertson EJ,
- 428 Lauer GM, Reiner SL, Wherry EJ. Progenitor and terminal subsets of CD8+ T cells cooperate to
- 429 contain chronic viral infection. *Science* 2012; 338(6111):1220-1225.
- 430 37. Hasley RB, Hong C, Li W, Friesen T, Nakamura Y, Kim GY, Park JH, Hixon JA, Durum S, Hu Z,
- 431 Sneller MC, Oguariri R, Imamichi T, Lane HC, Catalfamo M. HIV immune activation drives
- 432 increased Eomes expression in memory CD8 T cells in association with transcriptional
- 433 **downregulation of CD127**. *Aids* 2013; 27(12):1867-1877.
- 434 38. van der Windt GJ, O'Sullivan D, Everts B, Huang SC, Buck MD, Curtis JD, Chang CH, Smith AM,
- 435 Ai T, Faubert B, Jones RG, Pearce EJ, Pearce EL. CD8 memory T cells have a bioenergetic
- 436 advantage that underlies their rapid recall ability. Proc Natl Acad Sci U S A 2013; 110(35):14336-
- 437 14341.
- 438 39. Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, Stelekati E, McLane
- 439 LM, Paley MA, Delgoffe GM, Wherry EJ. Bioenergetic Insufficiencies Due to Metabolic Alterations
- 440 Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8+ T Cell Exhaustion.
- 441 *Immunity* 2016.
- 442 40. van den Berg HA, Wooldridge L, Laugel B, Sewell AK. Coreceptor CD8-driven modulation of T
- 443 **cell antigen receptor specificity**. *J Theor Biol* 2007; 249(2):395-408.
- 444 41. Wooldridge L, Laugel B, Ekeruche J, Clement M, van den Berg HA, Price DA, Sewell AK. CD8
- 445 **controls T cell cross-reactivity**. *J Immunol* 2010; 185(8):4625-4632.

23

446	42. Park JH, J	Adoro S, Luca	s PJ, Sarafova SD	, Alag AS, Do	oan LL, Erma	n B, Liu X,	Ellmeier W,	Bosselut
-----	----------------	---------------	-------------------	---------------	--------------	-------------	-------------	----------

- 447 R, Feigenbaum L, Singer A. 'Coreceptor tuning': cytokine signals transcriptionally tailor CD8
- 448 **coreceptor expression to the self-specificity of the TCR**. *Nat Immunol* 2007; 8(10):1049-1059.
- 449 43. Lachmann R, Bajwa M, Vita S, Smith H, Cheek E, Akbar A, Kern F. Polyfunctional T cells
- 450 accumulate in large human cytomegalovirus-specific T cell responses. J Virol 2012; 86(2):1001-
- 451 1009.
- 452 44. Balyan R, Gund R, Chawla AS, Khare SP, Pradhan SJ, Rane S, Galande S, Durdik JM, George A,

453 Bal V, Rath S. Correlation of Cell-Surface CD8 Levels with Function, Phenotype and

- 454 **Transcriptome of Naive CD8 T Cells**. *Immunology* 2018.
- 455 45. Eller MA, Goonetilleke N, Tassaneetrithep B, Eller LA, Costanzo MC, Johnson S, Betts MR,
- 456 Krebs SJ, Slike BM, Nitayaphan S, Rono K, Tovanabutra S, Maganga L, Kibuuka H, Jagodzinski L,
- 457 Peel S, Rolland M, Marovich MA, Kim JH, Michael NL, Robb ML, Streeck H. Expansion of Inefficient

458 HIV-Specific CD8 T Cells during Acute Infection. J Virol 2016; 90(8):4005-4016.

- 459 46. Falanga YT, Frascoli M, Kaymaz Y, Forconi C, Ong'echa JM, Bailey JA, Berg LJ, Moormann AM.
- 460 High pathogen burden in childhood promotes the development of unconventional innate-like
- 461 **CD8+ T cells**. *JCI Insight* 2017; 2(15).
- 462 47. Koch S, Larbi A, Ozcelik D, Solana R, Gouttefangeas C, Attig S, Wikby A, Strindhall J, Franceschi
- 463 C, Pawelec G. Cytomegalovirus infection: a driving force in human T cell immunosenescence.
- 464 Ann N Y Acad Sci 2007; 1114:23-35.
- 465 48. Henson SM, Lanna A, Riddell NE, Franzese O, Macaulay R, Griffiths SJ, Puleston DJ, Watson AS,
- 466 Simon AK, Tooze SA, Akbar AN. p38 signaling inhibits mTORC1-independent autophagy in
- 467 senescent human CD8(+) T cells. J Clin Invest 2014; 124(9):4004-4016.

- 468 49. Dumauthioz N, Tschumi B, Wenes M, Marti B, Wang H, Franco F, Li W, Lopez-Mejia IC, Fajas L,
- 469 Ho PC, Donda A, Romero P, Zhang L. Enforced PGC-1alpha expression promotes CD8 T cell
- 470 **fitness, memory formation and antitumor immunity**. *Cellular & molecular immunology* 2020.
- 471 50. Compston LI, Li C, Sarkodie F, Owusu-Ofori S, Opare-Sem O, Allain JP. Prevalence of persistent
- 472 and latent viruses in untreated patients infected with HIV-1 from Ghana, West Africa. Journal of
- 473 *medical virology* 2009; 81(11):1860-1868.